Work Here?
Nanovation Therapeutics
Work Here?
Develops lipid nanoparticle nucleic acid therapies
Nanovation Therapeutics
Work Here?
Develops lipid nanoparticle nucleic acid therapies
Overview
NTx develops lipid nanoparticle (LNP) platforms to deliver nucleic acid therapies, including mRNA, to specific tissues. Its products are scalable, customizable LNP formulations usable across routes of administration, offered through partnerships, licensing, and direct sales to pharma companies and research institutions. The company differentiates itself with a next‑generation LNP platform and a global network of NanoVation GENErators hubs that foster international collaboration and rapid development. Its goal is to improve delivery efficiency, safety, and durability of genetic medicines to make more diseases manageable or curable.
About Nanovation Therapeutics
Industries
Biotechnology
Healthcare
Company Size
11-50
Company Stage
Grant
Total Funding
$300K
Headquarters
Vancouver, Canada
Founded
2020
Get referred to Nanovation Therapeutics
See people who can refer or advise you
Simplify's Take
What believers are saying
- Novo Nordisk expanded NanoVation's deal to up to $600 million in September 2024.
- Convergent Ventures led a new funding round and added Zach Jonasson and David Main.
- A 2026 Chinese patent publication shows continued pipeline expansion around unshielded lipid nanoparticles.
What critics are saying
- Acuitas, Beam, Intellia, and Moderna crowd the same nonviral delivery market.
- NanoVation's Novo programs still need years before clinical proof or milestone payouts.
- If lcLNP fails beyond-liver delivery, NanoVation becomes a platform with no moat.
What makes Nanovation Therapeutics unique
- NanoVation's lcLNP platform targets cells outside the liver, a hard delivery problem.
- Novo Nordisk licensed NanoVation's LNPs for two base-editing therapies and five more targets.
- NanoVation holds 31 patent documents, including 25 pending filings around ionizable lipids.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$300k
Above
Industry Average
Funded Over
1 Rounds
Benefits
Health Insurance
Dental Insurance
Life Insurance
Performance Bonus
Paid Vacation
Paid Sick Leave
Company Stock Options
Professional Development Budget
Growth & Insights and Company News
6 month growth
↑ 4%1 year growth
↑ 0%2 year growth
↑ 2%Biotech is thrilled to share that NanoVation Therapeutics has been awarded the prestigious Deal of the Year award at the 27th Annual Life Sciences BC Awards!
NanoVation Therapeutics announced the expansion of its Board of Directors and the completion of a funding round led by Convergent Ventures. This follows a partnership with Novo Nordisk worth up to $600 million to develop genetic medicines. The funding will advance NanoVation's lipid nanoparticle technology for RNA delivery. New board members include Zachariah Jonasson and David Main, bringing extensive biotech experience.
NanoVation Therapeutics announced the expansion of its Board of Directors and the completion of a funding round led by Convergent Ventures. This follows a partnership with Novo Nordisk worth up to $600 million. The funding will advance NanoVation's lipid nanoparticle technology for RNA delivery. New board members include Zachariah Jonasson, CFO and CBO of Absci, and David Main, CEO of Notch Therapeutics, bringing expertise in biotech growth and strategic partnerships.
NanoVation Therapeutics announces expansion of Board of Directors and completion of funding round led by Convergent Ventures.
Nanovation Therapeutics partners with Novo Nordisk on genetic medicines for cardiometabolic and rare diseases.
Nanovation Therapeutics is Hiring for 1 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Nanovation Therapeutics
Industries
Biotechnology
Healthcare
Company Size
11-50
Company Stage
Grant
Total Funding
$300K
Headquarters
Vancouver, Canada
Founded
2020
Nanovation Therapeutics is Hiring for 1 Jobs on Simplify!
Find jobs on Simplify and start your career today